Cystic fibrosis was first identified as a distinct disease in 1938 by Dr. Dorothy Hansine Andersen, a pathologist at Columbia University in New York. Before her work, children with the condition died without anyone understanding what was killing them. Andersen’s discovery launched decades of research that transformed CF from a death sentence in infancy to a manageable chronic condition.
Signs in Folklore Before the Science
Long before anyone had a name for cystic fibrosis, people noticed something about certain babies. In medieval Europe, a folk saying warned: “Woe to the child who tastes salty from a kiss on the brow, for he is cursed and soon will die.” That saltiness on the skin, now understood as a hallmark of CF, was seen as a sign of witchcraft or a fatal curse. Parents had no way to explain why their children struggled to breathe or failed to thrive, and the vast majority of affected infants died before their second birthday.
Dorothy Andersen’s 1938 Discovery
The turning point came when Dr. Dorothy Andersen, working in a pathology lab, noticed an unusual lesion on the pancreas during an autopsy. Curious, she went back through years of autopsy records and medical literature, searching for similar cases. What she found was a clear disease pattern that no one had previously recognized. She named it “cystic fibrosis of the pancreas,” describing the scarred, cyst-filled tissue she kept finding in children who had died young. Her 1938 paper was the first to define CF as its own disease, and she later helped develop a diagnostic test for it.
At the time of Andersen’s description, CF was essentially a diagnosis made after death. The children she studied were typically infants under 18 months old who had already died from the disease’s effects.
Mucoviscidosis: A Broader Understanding
Within five years of Andersen’s discovery, researchers began to realize CF was more than a pancreatic disease. In 1943, Dr. Sydney Farber, chief of pathology at Boston Children’s Hospital, recognized that CF was a generalized disorder affecting organs beyond the pancreas. He introduced the term “mucoviscidosis,” referring to the thick, sticky mucus that characterizes the disease throughout the body. Farber described how this abnormally thick mucus obstructed the airways, prevented the lungs’ cleaning mechanisms from working properly, and set the stage for dangerous bacterial infections. The term mucoviscidosis is still used in parts of Europe today.
Finding the Gene in 1989
For fifty years after Andersen’s discovery, no one knew exactly what caused CF at a molecular level. That changed in September 1989, when a team of researchers at the Hospital for Sick Children in Toronto published a landmark paper in the journal Science. Led by John Riordan, Johanna Rommens, and Lap-Chee Tsui, the team identified the specific gene responsible for cystic fibrosis, located on chromosome 7. They called it the CFTR gene.
The protein this gene produces normally helps move salt and water in and out of cells. In most CF patients, a tiny deletion of just three DNA letters causes the protein to be missing a single amino acid. That one small defect is enough to produce the thick, dehydrated mucus that clogs the lungs, pancreas, and other organs. Finding the gene opened the door to understanding exactly why CF patients get sick, and eventually, to designing treatments that target the root cause rather than just managing symptoms.
From Infant Death to Decades of Life
The survival trajectory for people with CF tells the story of how far the science has come. In 1954, the median survival age was just four to five years. Most children with CF never started school. By 2019, the Cystic Fibrosis Foundation calculated that a child born that year with CF could expect to live to about 48 years old. That number continues to climb.
The biggest recent leap came in 2012, when the FDA approved the first drug designed to fix the faulty protein itself rather than treating downstream symptoms. This medication works specifically for patients with certain genetic mutations, correcting the way their cells handle salt and water. Since then, newer combination therapies have expanded eligibility to roughly 90% of CF patients, and the impact on lung function and quality of life has been dramatic. For children diagnosed today, the disease looks fundamentally different than it did even a generation ago.
Key Dates at a Glance
- 1938: Dorothy Andersen identifies CF as a distinct disease
- 1943: Sydney Farber coins “mucoviscidosis,” recognizing CF affects the whole body
- 1989: The CFTR gene is identified on chromosome 7
- 2012: The first drug targeting the underlying genetic defect wins FDA approval